CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML

PURPOSE: Ponatinib is the only approved tyrosine kinase inhibitor (TKI) suppressing BCR-ABL1(T315I)-mutated cells in chronic myeloid leukemia (CML). However, due to side effects and resistance, BCR-ABL1(T315I)-mutated CML remains a clinical challenge. Hydroxyurea (HU) has been used for cytoreduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneeweiss-Gleixner, Mathias, Byrgazov, Konstantin, Stefanzl, Gabriele, Berger, Daniela, Eisenwort, Gregor, Lucini, Chantal Blanche, Herndlhofer, Susanne, Preuner, Sandra, Obrova, Klara, Pusic, Petra, Witzeneder, Nadine, Greiner, Georg, Hoermann, Gregor, Sperr, Wolfgang R., Lion, Thomas, Deininger, Michael, Valent, Peter, Gleixner, Karoline V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921367/
https://www.ncbi.nlm.nih.gov/pubmed/31761618
http://dx.doi.org/10.1016/j.ebiom.2019.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921367/
https://www.ncbi.nlm.nih.gov/pubmed/31761618
http://dx.doi.org/10.1016/j.ebiom.2019.11.004

Ejemplares similares